2022 年第 8 期 第 17 卷

平腑调代方对肥胖2型糖尿病小鼠脂代谢和炎症及氧化应激水平的影响

Effects of Pingfutiaodai decoction on lipid metabolism, inflammation and oxidative stress in obese type 2 diabetic mice

作者：陈弘东1王耀献1刘伟敬1郭敬1张超1孙浩1娄文娇1贺仲晨2

英文作者：Chen Hongdong1 Wang Yaoxian1 Liu Weijing1 Guo Jing1 Zhang Chao1 Sun Hao1 Lou Wenjiao1 He Zhongchen2

单位：1北京中医药大学东直门医院肾病内分泌科，北京100700；2北京市和平里医院内分泌科，北京100013

英文单位：1Department of Nephrology and Endocrinology Dongzhimen Hospital of Beijing University of Chinese Medicine Beijing 100700 China; 2Department of Endocrinology Beijing Hepingli Hospital Beijing 100013 China

关键词：

英文关键词：Obese；Type2diabetesmellitus；Pingfutiaodaidecoction；Lipidmetabolism；Inflammatoryfactors；Oxidativestress

• 摘要：

• 目的 观察平腑调代方对肥胖2型糖尿病小鼠脂代谢、炎症及氧化应激水平的影响。方法 将36只无特定病原体级健康雄性6周龄C57BL/6J小鼠依据随机数字表法分为对照组、模型组和中药组，模型组选用高脂饲料联合链脲佐菌素诱导建立肥胖2型糖尿病小鼠模型，并给予纯水灌胃干预，中药组诱导建立肥胖2型糖尿病小鼠模型并给予平腑调代方灌胃干预。对照组不诱导肥胖2型糖尿病模型并给予纯水灌胃干预。干预12周后，检测各组总胆固醇、三酰甘油、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、C反应蛋白（CRP）、白细胞介素6（IL-6）、肿瘤坏死因子α（TNF-α）、超氧化物歧化酶(SOD)、丙二醛、总抗氧化能力（T-AOC）水平。结果 造模结束后，剔除不达标小鼠，最终对照组10只小鼠，模型组与中药组各9只小鼠进行药物干预。干预12周后，模型组总胆固醇、三酰甘油、LDL-C水平高于对照组，HDL-C水平低于对照组，中药组总胆固醇、三酰甘油、LDL-C水平均低于模型组，HDL-C水平高于模型组(均P＜0.05)。模型组CRP、IL-6及TNF-α水平明显高于对照组，中药组CRP、IL-6、TNF-α水平低于模型组［（48±5）μg/L比（55±6）μg/L、（66.1±5.8）ng/L比（71.9±2.5）ng/L、（97±9）ng/L比（126±11）ng/L］（均P＜0.05）。模型组SOD、T-AOC水平低于对照组，丙二醛水平高于对照组，中药组SOD、T-AOC水平高于模型组，丙二醛水平低于模型组（均P＜0.05）。结论 平腑调代方能够改善肥胖2型糖尿病小鼠脂代谢紊乱，减轻炎症反应并提高抗氧化能力，对肥胖2型糖尿病的治疗有参考意义。

• Objective To observe the effects of Pingfutiaodai decoction on lipid metabolism, inflammation and oxidative stress in obese type 2 diabetic mice. Methods Totally 36 healthy male C57BL/6J mice without specific pathogens at the age of 6 weeks were divided into control group, model group and traditional Chinese medicine group according to random number table method. The model group was induced to establish obese type 2 diabetic mice model by high-fat diet combined with streptozotocin and was given pure water gavage intervention. The traditional Chinese medicine group was induced to establish obese type 2 diabetic mice model and was given Pingfutiaodai decoction gavage intervention. The control group was not induced to obese type 2 diabetic model and was given pure water gavage intervention. After 12 weeks of intervention, levels of total cholesterol, triacylglycerol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α（TNF-α）, superoxide dismutase (SOD), malondialdehyde and total-antioxidant capacity (T-AOC) were measured in each group. Results After modeling and removing non-compliance mice, 10 mice in the control group, 9 mice in the model group and 9 mice in the traditional Chinese medicine group were given drug intervention. Twelve weeks after intervention, the levels of total cholesterol, triglyceride and LDL-C in the model group were higher than those in the control group, and the level of HDL-C was lower than that in the control group; the levels of total cholesterol, triglyceride and LDL-C in the traditional Chinese medicine group were lower than those in the model group, and the level of HDL-C was higher than that in the model group(all P＜0.05). The levels of CRP, IL-6 and TNF-α in the model group were higher than those in the control group, and the levels in the traditional Chinese medicine group were lower than those in the model group［（48±5）μg/L vs （55±6）μg/L,（66.1±5.8）ng/L vs （71.9±2.5）ng/L,（97±9）ng/L vs （126±11）ng/L］(all P＜0.05). The levels of SOD and T-AOC in the model group were lower than those in the control group, and the level of malondialdehyde was higher than that in the control group; the levels of SOD and T-AOC in the traditional Chinese medicine group were higher than those in the model group, and the level of malondialdehyde was lower than that in the model group(all P＜0.05). Conclusion Pingfutiaodai decoction can improve the disorder of lipid metabolism, reduce inflammatory response and increase antioxidant capacity in obese type 2 diabetic mice, which has reference significance for the treatment of obese type 2 diabetes mellitus.